Skip to main content
main-content
Top

06-12-2019 | Linagliptin | ADA 2019 | Article

Clinical takeaway: The CAROLINA trial

John Wilding outlines the key take-home message from the CAROLINA trial comparing the cardiovascular risk profile of the dipeptidyl peptidase-4 inhibitor linagliptin and the sulfonylurea glimepiride (0:37).

Related topics

Image Credits